Table 1.
Pharmacokinetic parameters of carvedilol SR by each dose group
| Parametera | AUClast (ng·h/mL) | AUCinf (ng·h/mL) | Cmax (ng/mL) | t½β (h) | tmax (h) |
|---|---|---|---|---|---|
| 8 mg | 58.29 (66.83)b | 60.84 (65.11) | 6.93 (63.19) | 6.73 (42.75) | 5.98 (4.0, 8.0) |
| 16 mg | 100.3 (69.92) | 104.16 (68.85) | 12.26 (53.52) | 6.96 (39.41) | 6.0 (5.0, 8.0) |
| 32 mg | 184.11 (62.74) | 188.78 (62.95) | 22.6 (65.83) | 7.38 (41.33) | 6.0 (5.0, 15.98) |
| 64 mg | 413.51 (68.59) | 423.02 (68.32) | 46.31 (64.04) | 7.74 (47.67) | 6.02 (5.0, 8.02) |
| 128 mg | 689.35 (62.76) | 703.29 (63.95) | 77.04 (66.99) | 7.67 (41.93) | 6.02 (5.0, 11.98) |
Notes:
a
n=18.
b
Data presented as geometric mean CV, except for tmax, for which median (min, max) is shown.
Abbreviations: AUClast, area under the plasma concentration–time curve from time 0 to last measurable time point; AUCinf, area under the plasma concentration–time curve from time 0 to infinity; Cmax, measured peak plasma concentration; CV, coefficient of variation; t½β, terminal half-life; tmax, time to reach peak concentration; SR, sustained release.